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Background:  End stage renal disease patients on maintenance hemodialysis (MHD) are at increased risk for cardiovascular and all-cause 
mortality. MHD subjects also are at increased risk for osteodystrophy and osteoporosis. Multidetector computed tomography (MDCT) is used to 
assess coronary artery calcium (CAC) burden in MHD subjects. Traditionally, osteoporosis risk is assessed by bone mineral density (BMD) using dual 
energy x-ray absorptiometry (DXA). BMD can potentially be assessed via MDCT. This study looks at the prospect of using MDCT to assess both CAC 
and BMD.
Methods:  109 subjects on MHD underwent MDCT for CAC scoring. Of those subjects, 65 also underwent hip BMD and pelvic BMD assessment via 
MDCT and DXA respectively.
Results:  Mean CAC score for the study population was 1058.9±1467.1. Mean Hip BMD measured by MDCT was 0.76±0.22 gm/cm2. Mean Pelvic 
BMD via DXA was 1.02±0.18 gm/cm2. Pearson correlation between MDCT Hip BMD and DXA Pelvic BMD was 0.68 (P<0.0001).
Conclusions:  Data demonstrates good correlation between BMD measured with MDCT and DXA. The study shows the feasibility of potentially 
utilizing MDCT to assess both CAC and BMD in end stage renal disease subjects. 
